Search for content, post, videos

A1M Pharma enters research collaboration

A1M Pharma

A1M Pharma has signed a sponsored research collaboration agreement with the Fred Hutchinson Cancer Research Centre in Seattle, USA.

The purpose of the collaboration is to elucidate molecular and tissue-specific mechanisms of action of the endogenous protein A1M.

Within the frame of the collaboration, the internationally renowned nephrologist and researcher Dr Richard Zager of Fred Hutchinson Cancer Research Centre will be working closely with A1M scientists to broaden the knowledge of molecular and tissue-specific mechanisms of action of the endogenous protein A1M. This work will provide key information for understanding the required dosing of A1M for individual patients.

The results of this research will provide A1M Pharma and their partners with clear insights for regulatory submissions and the designing of clinical trials for both pre-eclampsia and other acute kidney injuries.  Moreover, this information will also assist A1M Pharma in the ongoing development of its large-scale pharmaceutical manufacturing processes.

“This cooperation will be an important part of our ongoing development work before future clinical studies and it is inspiring to have the opportunity to do this together with internationally renowned scientists such as Dr Richard Zager of the prestigious Fred Hutchinson Cancer Research Centre. The cooperation is at the same time an acknowledgement of A1M’s work with developing treatments based on the endogenous protein A1M which will strengthen the scientific basis for all of our development projects”, says A1M Pharma’s CEO, Tomas Eriksson.

“A1M Pharma’s drug candidate, based on the endogenous protein A1M, has delivered promising preclinical data for several indications with unmet medical needs  of global significance, such as pre-eclampsia and acute kidney injury. I therefore look forward to studying the underlying mechanisms of action together with the company’s team of prominent scientists. Pharmaceuticals based on endogenous substances is an interesting approach and the prospect of studying A1M, which is a very promising example of this, makes this research collaboration even more interesting”, says Dr Richard Zager of Fred Hutchinson Cancer Research Centre.

Source: A1M Pharma